NO20071446L - Endotelin A reseptor (ETA)-antagonister i kombinasjon med fosfodiesterase 5-inhibitorer (PDE5) og anvendelser derav. - Google Patents

Endotelin A reseptor (ETA)-antagonister i kombinasjon med fosfodiesterase 5-inhibitorer (PDE5) og anvendelser derav.

Info

Publication number
NO20071446L
NO20071446L NO20071446A NO20071446A NO20071446L NO 20071446 L NO20071446 L NO 20071446L NO 20071446 A NO20071446 A NO 20071446A NO 20071446 A NO20071446 A NO 20071446A NO 20071446 L NO20071446 L NO 20071446L
Authority
NO
Norway
Prior art keywords
eta
pde5
endothelin
phosphodiesterase
receptor
Prior art date
Application number
NO20071446A
Other languages
English (en)
Norwegian (no)
Inventor
Donald Keyser
Richard Dixon
Original Assignee
Encysive Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encysive Pharmaceuticals Inc filed Critical Encysive Pharmaceuticals Inc
Publication of NO20071446L publication Critical patent/NO20071446L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20071446A 2004-08-26 2007-03-16 Endotelin A reseptor (ETA)-antagonister i kombinasjon med fosfodiesterase 5-inhibitorer (PDE5) og anvendelser derav. NO20071446L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60446204P 2004-08-26 2004-08-26
US11/211,099 US20060205733A1 (en) 2004-08-26 2005-08-25 Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
PCT/US2005/030342 WO2006026395A1 (en) 2004-08-26 2005-08-26 Endothelin a receptor (eta) antagonists in combination with phosphodiesterase 5 inhibitors (pde5) and uses thereof

Publications (1)

Publication Number Publication Date
NO20071446L true NO20071446L (no) 2007-03-26

Family

ID=36000390

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071446A NO20071446L (no) 2004-08-26 2007-03-16 Endotelin A reseptor (ETA)-antagonister i kombinasjon med fosfodiesterase 5-inhibitorer (PDE5) og anvendelser derav.

Country Status (12)

Country Link
US (1) US20060205733A1 (pt)
EP (1) EP1789051A4 (pt)
JP (1) JP2008510830A (pt)
KR (1) KR20070074552A (pt)
AU (1) AU2005280077A1 (pt)
BR (1) BRPI0514666A (pt)
CA (1) CA2578044A1 (pt)
IL (1) IL181513A0 (pt)
MX (1) MX2007002311A (pt)
NO (1) NO20071446L (pt)
RU (1) RU2007110933A (pt)
WO (1) WO2006026395A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020573A2 (en) * 2004-08-11 2006-02-23 Barbeau Donald L Noncardiotoxic pharmaceutical compounds
US20070037831A1 (en) * 2004-11-18 2007-02-15 Cynthia Cuffie-Jackson Methods of using PDE 5 inhibitors for the treatment of congestive heart failure
DE102005016345A1 (de) * 2005-04-09 2006-10-12 Bayer Healthcare Ag Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
WO2007002125A1 (en) * 2005-06-23 2007-01-04 Schering Corporation Rapidly absorbing oral formulations of pde5 inhibitors
US20070196510A1 (en) * 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
RU2008136315A (ru) * 2006-03-13 2010-04-20 Инсайсив Фармасьютикалз, Инк. (US) Композиции ситаксентана натрия
CN101443329A (zh) 2006-03-13 2009-05-27 恩希赛弗制药公司 N-(4-氯-3-甲基-5-异唑基)2-[2-甲基-4，5-(亚甲基二氧基)苯乙酰基]噻吩-3-磺酰胺钠盐的多晶型物
WO2007106494A2 (en) * 2006-03-13 2007-09-20 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of diastolic heart failure
EP2037912A2 (en) * 2006-05-15 2009-03-25 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
FR2902009B1 (fr) * 2006-06-13 2012-12-07 Bioprojet Soc Civ Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire
WO2007146900A2 (en) * 2006-06-15 2007-12-21 Gilead Colorado, Inc. Antihypertensive therapy method
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
HUE025355T2 (en) 2006-12-12 2016-02-29 Gilead Sciences Inc Composition for treating pulmonary hypertension
WO2008088727A2 (en) 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
EA026578B1 (ru) 2007-01-22 2017-04-28 ДЖиТиЭкс, ИНК. Вещества, связывающие ядерные рецепторы
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US20090004268A1 (en) * 2007-03-13 2009-01-01 Given Bruce D Methods and Compositions for Treatment of an Interstitial Lung Disease
AU2013203192B2 (en) * 2007-06-11 2015-12-24 Edge Therapeutics Inc. A drug delivery system for the prevention of cerebral vasospasm
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
NZ599430A (en) * 2007-06-11 2014-03-28 Loch Macdonald R A drug delivery system for the prevention of cerebral vasospasm
EP2205265A1 (en) * 2007-09-11 2010-07-14 Mondobiotech Laboratories AG Use of the peptide thymosin beta 4 alone or in combination with cecropin a as a therapeutic agent
CN101891747B (zh) * 2010-07-02 2012-04-25 张南 抑制5型磷酸二酯酶的化合物及制备方法
NZ610012A (en) * 2010-10-15 2015-05-29 Gilead Sciences Inc Compositions and methods of treating pulmonary hypertension
JP6336899B2 (ja) 2011-04-05 2018-06-06 エッジ セラピューティクス インコーポレイテッド 脳血流に影響する脳損傷後の結果を改善するための脳室内ドラッグデリバリーシステム
US8592470B2 (en) * 2012-01-31 2013-11-26 Eisai R&D Management Co., Ltd. Sitaxentan derivative
US9399019B2 (en) 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof
WO2014138738A1 (en) * 2013-03-08 2014-09-12 Abbive Inc. Methods of treating acute kidney injury
JP2020500183A (ja) * 2016-10-27 2020-01-09 プルモキネ、インコーポレイテッド 肺高血圧症の治療のための併用療法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
ES2187234A1 (es) * 1999-04-30 2003-05-16 Lilly Icos Llc Forma de dosificacion oral para tratar la disfuncion sexual.
US6451807B1 (en) * 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
KR20030071880A (ko) * 2001-02-02 2003-09-06 메르크 파텐트 게엠베하 피라졸로[４,３-ｄ]피리미딘과 엔도델린 수용체 길항제또는 티에노피리미딘과 엔도델린 수용체 길항제를포함하여 이루어지는 약제학적 조성물
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination

Also Published As

Publication number Publication date
AU2005280077A1 (en) 2006-03-09
EP1789051A4 (en) 2009-10-21
RU2007110933A (ru) 2008-10-10
BRPI0514666A (pt) 2008-06-17
KR20070074552A (ko) 2007-07-12
US20060205733A1 (en) 2006-09-14
JP2008510830A (ja) 2008-04-10
CA2578044A1 (en) 2006-03-09
EP1789051A1 (en) 2007-05-30
WO2006026395A1 (en) 2006-03-09
MX2007002311A (es) 2008-03-10
IL181513A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
NO20071446L (no) Endotelin A reseptor (ETA)-antagonister i kombinasjon med fosfodiesterase 5-inhibitorer (PDE5) og anvendelser derav.
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
UY28958A1 (es) Nuevos derivados de piridazin-3(2h)-ona
NO20072322L (no) Laktamforbindelser og anvendelse derav som farmasoytiske midler
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
NO20081569L (no) Administrasjon av dipeptidylpeptildaseinhibitorer
NO20050514L (no) Sammensetning og antiviral aktivitet til substituerte azaindoloksoeddikpiperazinderivater
NO20063925L (no) Indazolderivater som inhibitorer av hormonsensitiv lipase
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
NO20081592L (no) Dipeptidylpeptidaseinhibitorer for behandling av diabetes
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20070372L (no) Amidoforbindelser og anvendelse derav som farmasoytiske preparater
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
WO2005030187A3 (en) Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
NO20072599L (no) Inhibitorer av 11-beta-hydroksyl steroid dehydrogenase Type 1 og fremgangsmater for anvendelse derav
NO20070529L (no) Kinazolindionderivater som parp-inhibitorer
WO2005039485A3 (en) Gsk-3 inhibitors and uses thereof
NO20010743L (no) Antivirale indoloksoacetyl-piperazin-derivater
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
NO20065442L (no) Amidoforbindelser og deres anvendelse som legemidler
NO20070334L (no) 4,6-disubstituerte pyrimidiner og deres anvendelse som proteinkinaseinhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application